Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Labs

Amgen

Baxter

Cerner

Quest Diagnostics

Eli Lilly

Merck

Pfizer

UnitedHealth Group

If any investor has stood the test of time, it is Warren Buffett, and with good reason.

10 Health Care Stocks Warren Buffett Owns That Offer Safety and Dependable Dividends

Alnylam Pharmaceuticals

Bristol-Myers

Regeneron Pharmaceuticals

Waters

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

The Vanguard Health Care Fund's Top 5 Trades

Poshmark

Walmart

There's a lot of panic selling going on as investors digest the latest inflation numbers and the likelihood of the Federal Reserve taking a more aggressive stance on interest rates. Our advice is to buy stocks from companies that have the pricing power to withstand the effects of inflation.

These Stocks Will Defy Inflation

This medical devices giant has a habit of crushing the market.

Inflation Is No Match for This Stock

AMSTERDAM--(BUSINESS WIRE)--Stryker has introduced the Tornier shoulder arthroplasty portfolio and launched its first new Tornier product, the Perform Humeral Stem, in Europe.

Stryker Introduces Tornier Shoulder Arthroplasty Portfolio and Launches New Tornier Perform Humeral System in Europe

Edwards Lifesciences

Intuitive Surgical

"I think there are some true steals are developing in the medical device space because of omicron," the "Mad Money" host said.

Jim Cramer says these three medical device stocks look like 'true steals' here

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat

Stryker Corp (NYSE: SYK) posted Q4 adjusted EPS of $2.71, down 3.6% Y/Y, missing the consensus of $2.72. "We delivered a strong year of financial results, despite the ongoing challenges of the pandemic," said Kevin Lobo, Chair & CEO.

Stryker Posts Mixed Bag Q4 Earnings, Issues FY22 Guidance Below Consensus

Stryker Corporation (SYK) CEO Kevin Lobo on Q4 2021 Results - Earnings Call Transcript

Stryker (SYK) delivered earnings and revenue surprises of -0.37% and 1.93%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stryker (SYK) Q4 Earnings Lag Estimates

Stryker Corp. reported higher fourth-quarter profit and sales on Thursday, but per-share earnings missed Wall Street's target.

Dow Jones Newswires: Stryker's Q4 EPS misses Wall Street target

Kalamazoo, Michigan, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2021:﻿﻿

Stryker reports 2021 operating results and 2022 outlook

Kalamazoo, Michigan, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) today announced that it is commencing, through a wholly owned subsidiary, Voice Merger Sub Corp., a cash tender offer to purchase all outstanding shares of common stock of Vocera Communications, Inc. (NYSE: VCRA) for $79.25 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2022, among Stryker, Voice Merger Sub Corp. and Vocera.

Stryker commences tender offer for all outstanding shares of common stock of Vocera Communications

Up to ~30% of Stryker's customers have elective issues; however, the underlying diseases are progressive so they delay rather than stop acquiring Stryker's products. COVID notwithstanding, Stryker remains in a strong financial position.

Stryker: COVID Delays And Digital Communications

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Stryker (SYK) Q4 Earnings Expected to Decline

ST. LOUIS--(BUSINESS WIRE)--Stryker's new Tornier Perform Patient-Matched Glenoid was used in a surgical procedure for the first time by Jay Keener, M.D., in St. Louis.

Stryker Announces First Patient Case Using New Tornier Perform® Patient-Matched Primary Reversed Glenoid

Vocera Communications

NEW ORLEANS, Jan. 7, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

VOCERA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vocera Communications, Inc. - VCRA

Stryker (SYK) inks a deal with Vocera to enhance its digital healthcare offerings.

Stryker (SYK) to Boost Digital Capabilities With New Buyout

The Vocera (VCRA) acquisition will help Stryker accelerate its digital goals to improve the lives of caregivers and patients.

Vocera (VCRA) to be Acquired by Stryker for $79.25 Per Share

Stryker (NYSE: SYK) announced it is buying Vocera Communications, Inc. (NYSE: VCRA) for approximately $3.09 billion. These are the details.

Why Stryker (SYK) Is Buying Vocera Communications (VCRA) For About $3.09 Billion

Vocera Communications Inc. (NYSE: VCRA) went up by 25% after it was announced that it was entering a definitive merger agreement with Stryker (NYSE: SYK) whereby Stryker would acquire its outstanding common stock shares for $79.25 per share. As a result, the total equity value will come to roughly $2.97 billion.

Vocera Communications up 25% after entering a definitive agreement with Stryker

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

Vocera Communications (VCRA) stock is on the move Thursday as investors react to news of Stryker (SYK) acquiring the company. The post VCRA Stock: 8 Things for Vocera Investors to Know About the Stryker Deal as Shares Soar appeared first on InvestorPlace.

VCRA Stock: 8 Things for Vocera Investors to Know About the Stryker Deal as Shares Soar

Stryker Corp. SYK, -1.99% said Thursday it'll pay $79.25 a share to acquire Vocera Communications Inc. VCRA, -6.73% in a deal that values the workflow and communication technology company at $3.09 billion. Stryker said Vocera "has emerged as a leading platform in the digital care coordination and communication category" and has expanded throughout the pandemic.

Vocera Communications shares rally on acquisition by Stryker

Kalamazoo, Michigan, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today a definitive merger agreement to acquire all of the issued and outstanding shares of common stock of Vocera Communications, Inc. (NYSE: VCRA) for $79.25 per share, or a total equity value of approximately $2.97 billion and a total enterprise value of approximately $3.09 billion (including convertible notes). Vocera, which was founded in 2000, has emerged as a leading platform in the digital care coordination and communication category. The importance of this growing segment has continued to expand throughout the pandemic as it aims to reduce cognitive overload for caregivers and enables them to deliver the best patient care possible.

News for Stryker Stock (SYK)